Valuation : IDEAYA Biosciences, Inc.

Market Cap 3.85B 3.31B 3.11B 2.84B 5.3B 365B 5.33B 36.86B 14.26B 186B 14.44B 14.13B 593B P/E 2026 *
-8.63x
P/E 2027 * -9.48x
Enterprise Value 2.85B 2.45B 2.31B 2.11B 3.93B 271B 3.95B 27.36B 10.59B 138B 10.72B 10.49B 440B EV / Sales 2026 *
72.5x
EV / Sales 2027 * 24.1x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
08-31 IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer CI
08-31 IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy MT
08-19 Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial MT
08-19 IDEAYA Biosciences, Inc. Enters Clinical Collaboration With Genentech To Evaluate IDE892 In Combination With RG6620 In MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer CI
08-07 Certain Pre-Funded Warrants of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-07 Certain Common Stock of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-07 Certain Stock Options of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-04 Wedbush Adjusts Price Target on IDEAYA Biosciences to $60 From $58, Maintains Outperform Rating MT
08-04 IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises MT
08-04 IDEAYA Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-04 Earnings Flash (IDYA) IDEAYA Biosciences Posts Q2 Net Loss $1.22 a Share, vs. FactSet Est of $1.18 Loss MT
08-04 Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M MT
07-27 IDEAYA Biosciences Initiates Part 2 Monotherapy Expansion In Phase 1/2 Study Evaluating IDE892 In MTAP-Deleted Pancreatic And Lung Cancers CI
1 day-1.46%
1 week-1.83%
Current month-2.19%
1 month+6.75%
3 months+24.59%
6 months+11.80%
Current year+13.45%
1 week 38.59
Extreme 38.59
41.48
1 month 35.66
Extreme 35.66
42.68
Current year 26.81
Extreme 26.81
42.68
1 year 23.53
Extreme 23.5255
42.68
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Director of Finance/CFO 51 2025-04-30
Chief Tech/Sci/R&D Officer 59 2022-11-20
Director TitleAgeSince
Chairman 51 2026-06-16
Chairman 67 -
Director/Board Member 71 2015-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Exercice

Controller/Auditor

28,650 0.0327%
6/16/26 Free

Director

20,000 0.0228%
3/2/26 Buy

Director

50,000 0.0570%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-1.83%+67.68%+40.02% 3.85B
-0.82%-3.77%-2.49%+14.92% 48.41B
-0.35%-0.22%+410.02%+551.98% 45.01B
-1.48%+2.17%+40.64%+23.61% 44.07B
-2.24%-2.44%+1.00%+81.65% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.76%+3.32% - - 17.77B
+0.64%+1.93%+20.80%+119.27% 16.5B
-0.56%-0.50%+11.39%+31.41% 14.45B
-1.66%+0.29%+74.80%+41.77% 13.77B
Average -0.98%+0.12%+70.84%+105.34% 27.78B
Weighted average by Cap. -1.03%-0.13%+86.24%+132.80%

Financials

2026 *2027 *
Net sales 39.36M 33.84M 31.84M 29.05M 54.22M 3.73B 54.5M 377M 146M 1.91B 148M 145M 6.07B 115M 99.3M 93.42M 85.25M 159M 10.95B 160M 1.11B 428M 5.6B 434M 424M 17.81B
Net income -432M -371M -349M -319M -595M -40.96B -598M -4.14B -1.6B -20.93B -1.62B -1.59B -66.62B -421M -362M -341M -311M -580M -39.93B -583M -4.04B -1.56B -20.41B -1.58B -1.55B -64.94B
Net Debt -991M -852M -802M -732M -1.37B -93.97B -1.37B -9.5B -3.68B -48.03B -3.72B -3.64B -153B -1.07B -918M -863M -788M -1.47B -101B -1.48B -10.23B -3.96B -51.72B -4.01B -3.92B -165B
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
26-09-08 US$39.26 -1.52% 395,621
26-09-04 US$39.86 -0.28% 448,007
26-09-03 US$39.97 -0.50% 567,895
26-09-02 US$40.17 +0.55% 765,285
26-09-01 US$39.95 -0.37% 587,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
39.86USD
Average target price
52.15USD
Spread / Average Target
+30.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDYA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!